Literature DB >> 16770766

The ontogeny of postingestive inhibitory stimuli: examining the role of CCK.

Aron Weller1.   

Abstract

Cholecystokinin (CCK) inhibits food intake in adults. This paper describes research examining the ability of CCK to affect feeding in infant rats and the role of CCK in the developmentally emerging ability of the rat pup to inhibit ingestion in response to sensory characteristics of food. First, data will be described from studies that asked if the CCK system is functional in preweanling rats. Specifically, these studies examined whether exogenous and endogenous CCK can decrease intake of the infant rat during independent ingestion (of a milk diet, away from the dam). In addition, the ability of exogenous CCK to activate central feeding-control areas in the brain stem and hypothalamus in infant rats was examined by C-FOS staining. Next, experiments examining which specific intake-inhibitory sensory aspects of food are mediated by CCK will be described. The volume, hypertonicity, fat, carbohydrate and protein content of a preload were separately manipulated in different studies, followed closely by a 30-min test meal. The selective CCK(1) receptor antagonist devazepide was used to assess CCK mediation of the control of intake produced by particular sensory aspects of food, at the earliest age in which this ability to control intake appears. Finally, the pattern of independent ingestion in infant OLETF rats lacking CCK(1) receptors was examined. The results suggest that the CCK intake-inhibitory mechanism is potentially available to the young, suckling pup even before it starts to feed on its own. However, it appears to mediate only a portion of the controls of intake during nursing and early stages of weaning. Some aspects of the CCK system (e.g., forebrain-hindbrain connections) and CCK's role in mediating the effects of other stimulus aspects of food apparently undergo a post-weaning maturational process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16770766     DOI: 10.1002/dev.20148

Source DB:  PubMed          Journal:  Dev Psychobiol        ISSN: 0012-1630            Impact factor:   3.038


  8 in total

1.  The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.

Authors:  Helen H Wang; Piero Portincasa; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2016-01-12       Impact factor: 4.686

2.  Differential growth patterns among healthy infants fed protein hydrolysate or cow-milk formulas.

Authors:  Julie A Mennella; Alison K Ventura; Gary K Beauchamp
Journal:  Pediatrics       Date:  2010-12-27       Impact factor: 7.124

3.  Attenuation of obesity by early-life food restriction in genetically hyperphagic male OLETF rats: peripheral mechanisms.

Authors:  Mariana Schroeder; Timothy H Moran; Aron Weller
Journal:  Horm Behav       Date:  2010-02-13       Impact factor: 3.587

4.  Maternal environmental contribution to adult sensitivity and resistance to obesity in Long Evans rats.

Authors:  Mariana Schroeder; Liat Shbiro; Timothy H Moran; Aron Weller
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

5.  Altered basal and stimulated accumbens dopamine release in obese OLETF rats as a function of age and diabetic status.

Authors:  Elmira Anderzhanova; Mihai Covasa; Andras Hajnal
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-06-06       Impact factor: 3.619

Review 6.  Unraveling the obesity of OLETF rats.

Authors:  Timothy H Moran
Journal:  Physiol Behav       Date:  2007-11-29

7.  Examining maternal influence on OLETF rats' early overweight: insights from a cross-fostering study.

Authors:  Mariana Schroeder; Michal Schechter; Ester Fride; Timothy H Moran; Aron Weller
Journal:  Dev Psychobiol       Date:  2009-05       Impact factor: 3.038

8.  Development of obesity in the Otsuka Long-Evans Tokushima Fatty rat.

Authors:  Mariana Schroeder; Orna Zagoory-Sharon; Liat Shbiro; Asaf Marco; Jayson Hyun; Timothy H Moran; Sheng Bi; Aron Weller
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-09-30       Impact factor: 3.619

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.